EXOZ חוב כולל להון Invizyne

The future of eXoZymes Inc (EXOZ) relies on the development of cell-free synthesis, where success depends on the cost of bioenzymes and the demand for green chemistry. The Invizyne brand has earned a reputation as a bold visionary in synthetic biology, strengthening the trust of industrial partners. The business is based on creating enzyme foundations for biotech, ensuring high margins. This chart of share price quotes demonstrates that the total debt-to-equity ratio is 0.32.

This ratio determines the degree of business dependence on borrowed funds relative to equity. The calculation logic compares total liabilities with net assets to identify the risk of excessive leverage. By analyzing the current leverage ratio (total debt to equity), an investor assesses the stability of the financing structure. For eXoZymes Inc (EXOZ), this metric is critical, as the absence of operating cash flows leaves the company vulnerable to debt. In the context of scientific research and development, an increase in this indicator may signal a shortage of resources for the commercialization of technologies.